人工智能应用于肝病组学数据:迈向个体化诊断、预后与治疗
本综述概述了人工智能(AI)方法在肝病组学数据分析中的应用现状,梳理了不同肝病中各組学层面的研究分布及所用AI方法,指出转录组与基因组分析占主导,而蛋白质组与甲基化组探索相对稀少,并讨论了多组学数据不足、模型训练验证及临床实用性等挑战与应对策略。
要点
- 转录组和基因组分析在肝病AI组学研究中占主导,蛋白质组和甲基化组探索相对稀少。
- 公共数据库如癌症基因组图谱和国际癌症基因组联盟推动了肝细胞癌诊疗进展,但其他肝病的大型组学数据仍有限。
- 全球慢性肝病负担重,亟需建立多中心合作以生成大规模组学数据用于早期识别和干预。
核心结论
- AI与组学技术正推动肝病个体化诊断、预后和治疗策略的进步。
- 多组学数据匮乏和AI方法处理复杂数据集的挑战仍需通过多中心合作和探索先进AI方法来解决。
研究设计与样本
- 综述,检索并汇总了AI方法应用于肝病组学数据分析的现有研究。
主要发现
- 转录组和基因组分析在肝病AI组学研究中占主导,蛋白质组和甲基化组等其他层面探索相对稀少。
- 癌症基因组图谱和国际癌症基因组联盟等公共数据库推动了肝细胞癌诊疗进展,但其他肝病的大型组学数据仍有限。
- 将复杂AI方法应用于多组学数据集面临数据量不足、模型训练验证及取得无偏且具临床实用性结果的挑战。
局限性
- 其他肝病的大型组学数据集仍然有限。
- 将复杂AI方法应用于多组学数据集需要大量数据来训练和验证模型,并面临取得无偏且具临床实用性结果的挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advancements in omics technologies and artificial intelligence (AI) methodologies are fuelling our progress towards personalised diagnosis, prognosis and treatment strategies in hepatology. This review provides a comprehensive overview of the current landscape of AI methods used for analysis of omics data in liver diseases. We present an overview of the prevalence of different omics levels across various liver diseases, as well as categorise the AI methodology used across the studies. Specifically, we highlight the predominance of transcriptomic and genomic profiling and the relatively sparse exploration of other levels such as the proteome and methylome, which represent untapped potential for novel insights. Publicly available database initiatives such as The Cancer Genome Atlas and The International Cancer Genome Consortium have paved the way for advancements in the diagnosis and treatment of hepatocellular carcinoma. However, the same availability of large omics datasets remains limited for other liver diseases. Furthermore, the application of sophisticated AI methods to handle the complexities of multiomics datasets requires substantial data to train and validate the models and faces challenges in achieving bias-free results with clinical utility. Strategies to address the paucity of data and capitalise on opportunities are discussed. Given the substantial global burden of chronic liver diseases, it is imperative that multicentre collaborations be established to generate large-scale omics data for early disease recognition and intervention. Exploring advanced AI methods is also necessary to maximise the potential of these datasets and improve early detection and personalised treatment strategies.
引用
- Ghosh S, Zhao X, Alim M, et al. Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment. Gut. 2025. PMID: 39174307. doi:10.1136/gutjnl-2023-331740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。